We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Gains Ground on New Applications, Grows in Australia
Read MoreHide Full Article
Varian Medical Systems recently announced that Australia-based Peter MacCallum Cancer Centre (also known as Peter Mac) has selected the company’s flagship Eclipse treatment planning system to replace the existing cancer treatment platform across all sites. Notably, Varian registered this order in the fourth quarter of fiscal 2017.
The Eclipse treatment planning system is an integrated and comprehensive platform, which supports radiation treatment such as photon, FFF beams, protons, electrons, external beams, low-dose-rate brachytherapy and cobalt therapy. The system creates optimized radiotherapy treatment plan for patients.
The platform is supposedly the first Microsoft Azure-hosted system to be deployed in Australia. In fact, the latest development includes the introduction of Varian’s Velocity platform to Peter Mac for adaptive radiotherapy.
Newer Applications Gain Prominence
Varian continues to witness strong market acceptance of its software solutions, particularly for Eclipse treatment planning and ARIA oncology information systems. Other new applications such as RapidPlan, multi-criteria optimization, InSightive analytics solution, 360 Oncology cloud-based cancer operating platform and the Velocity longitudinal cancer imaging solution have been fortifying the company’s foothold.
The launches of Halcyon and HyperArc platforms in 2017 are noteworthy. The platforms are used for cancer treatment through image-guided volumetric intensity modulated radiotherapy.
Varian operates in a technology-driven environment where success depends on innovation and frequent product updates. The company has been successful on the R&D front, evident from year-over-year expansion in its top line. The company’s other varied offerings include TrueBeam and Edge platforms, Qumulate QA and RapidPlan knowledge-based treatment planning. We believe that Varian’s innovative product pipeline will continue to drive overall growth over the long term.
Market Potential
A research report by Markets And Markets suggests that the global radiotherapy market is projected to reach a worth of $9.47 billion by 2022, up from $6.81 billion in 2017, at a CAGR of 6.8%.
Further, Global Information Inc. suggests that the radiotherapy markets in APAC are expected to reach a worth of $2.34 billion by 2024 at a CAGR of 11.5% in the 2017-2024 period. Per the report, APAC has been segregated into 11 geographical divisions, wherein Australia is a major contributor to radiotherapy revenues. Varian has been the key player in the region, followed by Elekta AB (EKTAY - Free Report) and Accuray, Inc (ARAY - Free Report) .
International Growth in Focus
In November, Varian announced plans of opening a facility in Jundiai, Brazil, reflecting long-term commitment and partnership with the Brazilian Ministry of Health. The facility will provide access to advanced radiotherapy treatment in Latin America, particularly in the Brazilian oncology market.
The development closely follows the receipt of Shonin approval from the Japan Ministry of Health, Labor and Welfare to market the Varian Halcyon system.
Price Performance
Year to date, Varian has outperformed the industry in terms of price performance. Shares have returned 40.9%, comparing favorably with the sub-industry’s rally of just 24.3%. Also, the current return is higher than the S&P 500’s gain of 22.9%.
Zacks Rank & Key Pick
Varian has a Zacks Rank #4 (Sell).
A better-ranked stock in the broader medical space is The Cooper Companies Inc. (COO - Free Report) . The stock sports a Zacks Rank #1 (Strong Buy) and has a long-term expected earnings growth rate of 10.8%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Varian Gains Ground on New Applications, Grows in Australia
Varian Medical Systems recently announced that Australia-based Peter MacCallum Cancer Centre (also known as Peter Mac) has selected the company’s flagship Eclipse treatment planning system to replace the existing cancer treatment platform across all sites. Notably, Varian registered this order in the fourth quarter of fiscal 2017.
The Eclipse treatment planning system is an integrated and comprehensive platform, which supports radiation treatment such as photon, FFF beams, protons, electrons, external beams, low-dose-rate brachytherapy and cobalt therapy. The system creates optimized radiotherapy treatment plan for patients.
The platform is supposedly the first Microsoft Azure-hosted system to be deployed in Australia. In fact, the latest development includes the introduction of Varian’s Velocity platform to Peter Mac for adaptive radiotherapy.
Newer Applications Gain Prominence
Varian continues to witness strong market acceptance of its software solutions, particularly for Eclipse treatment planning and ARIA oncology information systems. Other new applications such as RapidPlan, multi-criteria optimization, InSightive analytics solution, 360 Oncology cloud-based cancer operating platform and the Velocity longitudinal cancer imaging solution have been fortifying the company’s foothold.
The launches of Halcyon and HyperArc platforms in 2017 are noteworthy. The platforms are used for cancer treatment through image-guided volumetric intensity modulated radiotherapy.
Varian operates in a technology-driven environment where success depends on innovation and frequent product updates. The company has been successful on the R&D front, evident from year-over-year expansion in its top line. The company’s other varied offerings include TrueBeam and Edge platforms, Qumulate QA and RapidPlan knowledge-based treatment planning. We believe that Varian’s innovative product pipeline will continue to drive overall growth over the long term.
Market Potential
A research report by Markets And Markets suggests that the global radiotherapy market is projected to reach a worth of $9.47 billion by 2022, up from $6.81 billion in 2017, at a CAGR of 6.8%.
Further, Global Information Inc. suggests that the radiotherapy markets in APAC are expected to reach a worth of $2.34 billion by 2024 at a CAGR of 11.5% in the 2017-2024 period. Per the report, APAC has been segregated into 11 geographical divisions, wherein Australia is a major contributor to radiotherapy revenues. Varian has been the key player in the region, followed by Elekta AB (EKTAY - Free Report) and Accuray, Inc (ARAY - Free Report) .
International Growth in Focus
In November, Varian announced plans of opening a facility in Jundiai, Brazil, reflecting long-term commitment and partnership with the Brazilian Ministry of Health. The facility will provide access to advanced radiotherapy treatment in Latin America, particularly in the Brazilian oncology market.
The development closely follows the receipt of Shonin approval from the Japan Ministry of Health, Labor and Welfare to market the Varian Halcyon system.
Price Performance
Year to date, Varian has outperformed the industry in terms of price performance. Shares have returned 40.9%, comparing favorably with the sub-industry’s rally of just 24.3%. Also, the current return is higher than the S&P 500’s gain of 22.9%.
Zacks Rank & Key Pick
Varian has a Zacks Rank #4 (Sell).
A better-ranked stock in the broader medical space is The Cooper Companies Inc. (COO - Free Report) . The stock sports a Zacks Rank #1 (Strong Buy) and has a long-term expected earnings growth rate of 10.8%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>